lingfert.blogg.se

Captor therapeutics
Captor therapeutics





captor therapeutics

Captor has appointed Wedbush Securities Inc., a US-based investment banking firm specialised in healthcare, to assist the company in evaluating the market situation and considering options for raising financing.

captor therapeutics

In keeping with Captor's global ambitions, the authorised share capital may be used to raise financing on the international capital markets and/or on the domestic market in Poland. Introducing the authorised share capital in advance of any capital raising will provide Captor with the flexibility to optimize the timing and take advantage of opportunities in the market as they arise. In advance of any capital raising, Captor is seeking approval from its shareholders to introduce the authorised share capital. In the budget for 2023-2025, the company anticipates spending approximately USD 74m and assumes that the above strategic expenditures will be financed by existing cash, committed grants, reimbursement from existing collaborations and at the appropriate time, raising additional capital. Our team diligently monitors advancements in the TPD domain, and we are confident in our world-class group of experts in protein, structure, engineering, and biophysics who are pioneering the discovery of novel E3 ligases.” We are thrilled with the exceptional pre-clinical efficacy shown in the CT-01 and CT-03 projects as we take these programs to the clinic to provide superior care for cancer patients. Michał Walczak, CSO of Captor Therapeutics, said:“The field of Targeted Protein Degradation is advancing rapidly, with 18 degraders currently in clinical development to address life-threatening and life-impairing diseases.

captor therapeutics

Build on Captor's solid European listing and investor base to attract US investors, potentially culminating in a US NASDAQ presence (through an ADR or direct listing), subject to favorable capital market conditions.Fully exploit the partnering opportunities that these technology developments provide. Deepen and expand the OptigradeTM platform through degrading targets with high clinical potential by leveraging Captor's novel E3 ligase ligands and expanding the use of high potency degraders into the antibody drug conjugate space.Advance Captor's early pipeline assets in inflammation (CT-02, CT-05) to in-vivo proof of efficacy in 2023 as a prelude to collaborative development.Initiate the clinical development by Captor of its advanced projects CT-01 (Hepatocellular carcinoma) and CT-03 (haematological malignancies) in 20 respectively, with clinical data readouts in 20.The main strands to the 2023-2025 plan are: We look forward to embarking on this journey with our current and future partners and shareholders.” We have set an ambitious plan to fast forward the development of our pipeline and take two assets into the clinic, balancing risk and reward and allowing maximal growth in company value. Since our IPO in 2021, these advances have allowed Captor to come through the recently challenging Biotech market much better than most European and US Biotech companies. Tom Shepherd, CEO of Captor Therapeutics, said:“We have made great progress with taking our highly differentiated pipeline toward the clinic, keeping our TPD platform at the cutting edge of developments in the field, and signing a major strategic collaboration. to develop novel degraders against a neurodegeneration target.ĭr. The capabilities of the OptigradeTM platform were further validated by the signature late last year of a significant collaboration with Ono Pharmaceutical Co., Ltd. Regarding the OptigradeTM platform, recent breakthroughs related to the development of high affinity ligands targeting novel E3 ubiquitin ligases, understanding these ligases' 3D architecture at high resolution atomic level, and new highly potent degraders (pico-molar degradation potency), are laying the foundation for a next generation degrader pipeline.

captor therapeutics

Captor's fully-owned lead assets are in IND-enabling studies and have both demonstrated compelling efficacy in animal models of hepatocellular cancer and haematological malignancies respectively. The 2023-2025 plan builds on the excellent progress made over the last 18 months with Captor's two lead pipeline assets as well as major advances in the OptigradeTM TPD platform. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical stage, major international player in the rapidly growing TPD space. WROCŁAW, Poland, Ma(GLOBE NEWSWIRE) - Captor Therapeutics S.A.







Captor therapeutics